Henderson Group Plc Janus Purchases 28,326 Shares of ARCA biopharma, Inc. (NASDAQ:ABIO) Stock

ARCA biopharma, Inc. (NASDAQ:ABIO) major shareholder Henderson Group Plc Janus purchased 28,326 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The stock was bought at an average price of $3.43 per share, for a total transaction of $97,158.18. Following the transaction, the insider now directly owns 1,676,903 shares of the company’s stock, valued at approximately $5,751,777.29. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Henderson Group Plc Janus also recently made the following trade(s):

• On Wednesday, July 10th, Henderson Group Plc Janus acquired 55,463 shares of ARCA biopharma stock. The shares were purchased at an average price of $3.46 per share, for a total transaction of $191,901.98.
• On Monday, July 8th, Henderson Group Plc Janus bought 47,492 shares of ARCA biopharma stock. The stock was purchased at an average price of $3.46 per share, with a total value of $164,322.32.
• On Wednesday, July 3rd, Henderson Group Plc Janus purchased 166,042 shares of ARCA biopharma stock. The shares were purchased at an average price of $3.55 per share, for a total transaction of $589,449.10.

ARCA biopharma Stock Up 0.9 %

NASDAQ:ABIO opened at $3.35 on Friday. ARCA biopharma, Inc. has a twelve month low of $1.56 and a twelve month high of $4.49. The stock’s 50-day simple moving average is $3.43 and its 200 day simple moving average is $2.54. The firm has a market capitalization of $48.60 million, a PE ratio of -7.98 and a beta of 0.90.

ARCA biopharma (NASDAQ:ABIO) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($0.14) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on ARCA biopharma in a research note on Wednesday, May 22nd. They set a “sell” rating for the company.

Hedge Funds Weigh In On ARCA biopharma

A hedge fund recently bought a new stake in ARCA biopharma stock. abrdn plc bought a new position in shares of ARCA biopharma, Inc. (NASDAQ:ABIO) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 32,461 shares of the biopharmaceutical company’s stock, valued at approximately $55,000. Institutional investors own 56.44% of the company’s stock.

ARCA biopharma Company Profile

ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.